


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): A compound of formula (I):




wherein

ring A, ring B, and ring D each independently represents a cyclic group which may be substituted;


J represents a bond or a spacer having 1 to 8 atoms in its main chain; and

G represents a bond or a spacer having 1 to 4 atoms in its main chain;

wherein



is




wherein R<sup>D</sup> represents a substituent of ring D;

==== represents a single bond or a double bond; and

M represents a 3- to 11-membered monocyclic or bicyclic cyclic group which may be substituted;

ring B is a C<sub>3-8</sub> monocyclic carbocyclic ring which may be substituted or a 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s) which may be substituted;

J is



wherein R<sup>3</sup> and R<sup>4</sup> each independently represents hydrogen or C<sub>1-8</sub> alkyl; and

E represents a bond or a spacer having 1 to 6 atoms in its main chain;


G is -NR<sup>T1</sup>-SO<sub>2</sub>-

wherein R<sup>T1</sup> represents hydrogen, C<sub>1-8</sub> alkyl which may be substituted, C<sub>2-8</sub> alkenyl which may be substituted, C<sub>2-8</sub> alkynyl which may be substituted or a 3- to 8-membered cyclic group which may be substituted;


or a salt thereof.

Claims 2-6. (canceled).

7. (currently amended): The compound according to claim 6, wherein



is



wherein

R<sup>D</sup> has the same meaning as described in claim 61.

8. (original): The compound according to claim 1, wherein ring A is a carbocyclic ring which may be substituted.

9. (original): The compound according to claim 1, wherein ring A is a heterocyclic ring which may be substituted.

10. (original): The compound according to claim 8, wherein the carbocyclic ring is a C<sub>3-15</sub> monocyclic, bicyclic or tricyclic carbocyclic ring.

11. (original): The compound according to claim 9, wherein the heterocyclic ring is a 3- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s).

12. (original): The compound according to claim 10, wherein the carbocyclic ring is a benzene ring or a naphthalene ring.

13. (original): The compound according to claim 11 wherein the heterocyclic ring is a pyridine ring, a pyrazole ring, a dioxaindane ring or a benzodioxane ring.

Claims 14 - 19. (canceled).

20. (currently amended): The compound according to claim ~~18~~1, wherein the C<sub>3-8</sub> monocyclic carbocyclic ring represented by ring B is a benzene ring.

21. (currently amended): The compound according to claim ~~19~~1, wherein the 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s) represented by ring B is a pyridine ring or a thiophene ring.

Claims 22-24. (canceled).

25. (currently amended): The compound according to claim ~~24~~1, wherein R<sup>3</sup> and R<sup>4</sup> each independently represents hydrogen or methyl.

26. (currently amended): The compound according to claim ~~24~~1, wherein E is a bond[[,]].

27. (currently amended): The compound according to claim ~~24~~1, wherein E is a spacer having 1 to 6 atoms in its main chain.

28. (original): The compound according to claim 27, wherein E is C<sub>1-4</sub> alkylene or C<sub>1-3</sub> alkyleneoxy.


29. (original): The compound according to claim 28, wherein E is methylene or methylenoxy.

30. (canceled).

31. (canceled).

32. (currently amended): The compound according to claim ~~31~~1, wherein G is -NH-SO<sub>2</sub>-.

33. (currently amended): The compound according to claim 1, wherein the compound is a compound of formula (A):



wherein

R<sup>1</sup> and R<sup>2</sup> each independently represents (1) hydrogen, (2) C<sub>1-8</sub> alkyl, (3) C<sub>2-8</sub> alkenyl, (4) C<sub>2-8</sub> alkynyl, (5) halogen, (6) cyano, (7) nitro, (8) -CONR<sup>7</sup>R<sup>8</sup>, (9) -COOR<sup>9</sup>, (10) Cyc1 or (11) C<sub>1-8</sub> alkyl substituted with 1 to 5 groups selected from (a) -CONR<sup>7</sup>R<sup>8</sup>, (b) -COOR<sup>9</sup>, (c) -OR<sup>10</sup>, (d) -NR<sup>11</sup>R<sup>12</sup>, (e) halogen, and (f) Cyc1; or

R<sup>1</sup> and R<sup>2</sup> are taken together to represent C<sub>3-4</sub> alkylene, -CH=CH-CH<sub>2</sub>-, -CH<sub>2</sub>-CH=CH-, -CH=CH-CH=CH- or -CH=CH-CH<sub>2</sub>-CH<sub>2</sub>-, wherein the carbocyclic ring to be formed may be substituted with C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>1-8</sub> alkoxy, halogen, cyano, nitro or

hydroxyl, wherein  $R^7$  and  $R^8$  each independently represents (1) hydrogen, (2)  $C_{1-8}$  alkyl, (3)  $C_{2-8}$  alkenyl, (4)  $C_{2-8}$  alkynyl, (5) Cyc2, (6)  $-OR^{13}$  or (7)  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl or  $C_{2-8}$  alkynyl substituted with 1 to 5 groups selected from (a)  $-OR^{13}$ , (b)  $-NR^{14}R^{15}$ , (c)  $-NR^{16}COR^{17}$ , (d) halogen, (e)  $CF_3$ , and (f) Cyc2; or  $R^7$  and  $R^8$  are taken together with the adjacent nitrogen atom to represent a 3- to 8-membered monocyclic heterocyclic ring having at least one nitrogen atom as a hetero atom(s) and 0 to 3 nitrogen atoms, 0 to 1 oxygen atom and/or 0 to 1 sulfur atom as an other hetero atom(s), wherein the heterocyclic ring may be substituted with (a)  $C_{1-8}$  alkyl, (b) halogen, (c) hydroxyl, or (d)  $C_{1-8}$  alkyl substituted with hydroxyl;

$R^{13}$  to  $R^{17}$  each independently represents (1) hydrogen, (2)  $C_{1-8}$  alkyl, (3)  $C_{2-8}$  alkenyl, (4)  $C_{2-8}$  alkynyl, (5) Cyc1, or (6)  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl or  $C_{2-8}$  alkynyl substituted with Cyc1;

$R^9$  to  $R^{12}$  each independently represents (1) hydrogen, (2)  $C_{1-8}$  alkyl, (3)  $C_{2-8}$  alkenyl, (4)  $C_{2-8}$  alkynyl, (5) Cyc1, or (6)  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl or  $C_{2-8}$  alkynyl substituted with Cyc1;

Cyc1 represents a  $C_{3-15}$  monocyclic, bicyclic or tricyclic carbocyclic ring or a 3- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s), wherein Cyc1 may be substituted with 1 to 5 of  $R^{18}$ ;

$R^{18}$  represents (1)  $C_{1-8}$  alkyl, (2)  $C_{2-8}$  alkenyl, (3)  $C_{2-8}$  alkynyl, (4) halogen, (5) cyano, (6) nitro, (7) trifluoromethyl, (8) trifluoromethoxy, (9)  $-OR^{19}$ , (10)  $-SR^{20}$ , (11)  $-NR^{21}R^{22}$ , (12)  $-COR^{23}$ , (13)  $-COOR^{24}$ , (14)  $-NR^{25}COR^{26}$ , (15)  $-CONR^{27}R^{28}$ , (16) Cyc2, or (17)  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl or  $C_{2-8}$  alkynyl substituted with 1 to 5 groups selected from (a) halogen, (b) cyano, (c) nitro, (d) trifluoromethyl, (e) trifluoromethoxy, (f)  $-OR^{19}$ , (g)  $-SR^{20}$ , (h)  $-NR^{21}R^{22}$ , (i)  $-COR^{23}$ , (j)  $-COOR^{24}$ , (k)  $-NR^{25}COR^{26}$ , (l)  $-CONR^{27}R^{28}$ , and (m) Cyc2;

$R^{19}$  to  $R^{28}$  each independently represents (1) hydrogen, (2)  $C_{1-8}$  alkyl, (3)  $C_{2-8}$  alkenyl, (4)  $C_{2-8}$  alkynyl, (5) Cyc2, or (6)  $C_{1-8}$  alkyl,  $C_{2-8}$  alkenyl or  $C_{2-8}$  alkynyl substituted with Cyc2;

Cyc2 represents a  $C_{3-8}$  monocyclic carbocyclic ring or a 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s), wherein Cyc2 may be substituted with 1 to 5 of  $R^{29}$ ;

R<sup>29</sup> represents (1) C<sub>1-8</sub> alkyl, (2) C<sub>2-8</sub> alkenyl, (3) C<sub>2-8</sub> alkynyl, (4) halogen, (5) cyano, (6) nitro, (7) hydroxyl, (8) trifluoromethyl, (9) trifluoromethoxy, or (10) -OR<sup>100</sup>;

R<sup>100</sup> represents C<sub>1-8</sub> alkyl;

R<sup>3</sup> and R<sup>4</sup> each independently represents hydrogen or C<sub>1-8</sub> alkyl;

E<sup>1</sup> represents a bond or C<sub>1-6</sub> alkylene, wherein a carbon atom in the alkylene group may be substituted with oxygen, sulfur, or -NR<sup>30</sup>-;

R<sup>30</sup> represents (1) C<sub>1-8</sub> alkyl, (2) C<sub>2-8</sub> alkenyl, (3) C<sub>2-8</sub> alkynyl, (4) phenyl, or (5) C<sub>1-8</sub> alkyl substituted with phenyl;

ring A<sup>1</sup> represents a C<sub>3-15</sub> monocyclic, bicyclic or tricyclic carbocyclic ring or a 3- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s);

R<sup>5</sup> represents (1) C<sub>1-8</sub> alkyl, (2) C<sub>2-8</sub> alkenyl, (3) C<sub>2-8</sub> alkynyl, (4) halogen, (5) cyano, (6) nitro, (7) trifluoromethyl, (8) trifluoromethoxy, (9) -OR<sup>31</sup>, (10) -NR<sup>32</sup>R<sup>33</sup>, (11) -NR<sup>34</sup>COR<sup>35</sup>, (12) Cyc3, or (13) C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl or C<sub>2-8</sub> alkynyl substituted with 1 to 5 groups selected from (a) halogen, (b) cyano, (c) nitro, (d) trifluoromethyl, (e) trifluoromethoxy, (f) -OR<sup>31</sup>, (g) -NR<sup>32</sup>COR<sup>33</sup>, (h) -NR<sup>34</sup>COR<sup>35</sup>, and (i) Cyc3;

R<sup>31</sup> to R<sup>35</sup> each independently represents (1) hydrogen, (2) C<sub>1-8</sub> alkyl, (3) C<sub>2-8</sub> alkenyl, (4) C<sub>2-8</sub> alkynyl, (5) Cyc3, or (6) C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl or C<sub>2-8</sub> alkynyl substituted with 1 to 5 groups selected from (a) Cyc3, (b) -OR<sup>36</sup> and (c) -NR<sup>37</sup>R<sup>38</sup>;

R<sup>36</sup> to R<sup>38</sup> each independently represents (1) hydrogen, (2) C<sub>1-8</sub> alkyl, (3) -OR<sup>39</sup>, or (4) -NR<sup>40</sup>R<sup>41</sup>;

R<sup>39</sup> to R<sup>41</sup> each independently represents hydrogen or C<sub>1-8</sub> alkyl;

Cyc3 represents a C<sub>3-8</sub> monocyclic carbocyclic ring or a 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s);

ring B<sup>1</sup> represents a C<sub>3-8</sub> monocyclic carbocyclic ring or a 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as

~~a hetero atom(s)C<sub>3-15</sub> monocyclic, bicyclic or tricyclic carbocyclic ring or a 3- to 15-membered monocyclic, bicyclic or tricyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s);~~

R<sup>6</sup> represents (1) C<sub>1-8</sub> alkyl, (2) C<sub>2-8</sub> alkenyl, (3) C<sub>2-8</sub> alkynyl, (4) halogen, (5) cyano, (6) nitro, (7) trifluoromethyl, (8) trifluoromethoxy, (9) -OR<sup>42</sup>, (10) -NR<sup>43</sup>R<sup>44</sup>, (11) -SR<sup>101</sup>, (12) -SO<sub>2</sub>R<sup>102</sup>, (13) -COR<sup>103</sup>, (14) -COOR<sup>104</sup>, (15) Cyc2, or (16) C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl or C<sub>2-8</sub> alkynyl substituted with 1 to 5 groups selected from (a) -COOR<sup>104</sup>, (b) -NR<sup>105</sup>COR<sup>106</sup>, and (c) Cyc2;


R<sup>42</sup> to R<sup>44</sup> and R<sup>101</sup> to R<sup>106</sup> each independently represents (1) hydrogen, (2) C<sub>1-8</sub> alkyl, (3) Cyc2, or (4) -COR<sup>107</sup>, or (5) C<sub>1-8</sub> alkyl substituted with 1 to 5 halogen atoms;

R<sup>107</sup> represents C<sub>1-8</sub> alkyl; and

p and q each independently represents 0 or an integer of 1 to 5.

34. (withdrawn): A prodrug for the compound according to claim 1.

35. (currently amended): A pharmaceutical composition which comprises the compound of formula (I):



wherein


ring A, ring B, and ring D each independently represents a cyclic group which may be substituted;

J represents a bond or a spacer having 1 to 8 atoms in its main chain; and


G represents a bond or a spacer having 1 to 4 atoms in its main chain;



wherein



is




wherein  $R^D$  represents a substituent of ring D;

--- represents a single bond or a double bond; and

M represents a 3- to 11-membered monocyclic or bicyclic cyclic group which may be substituted;

ring B is a  $C_{3-8}$  monocyclic carbocyclic ring which may be substituted or a 3- to 8-membered monocyclic heterocyclic ring having 1 to 4 nitrogen atoms, 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms as a hetero atom(s) which may be substituted;

J is



wherein  $R^3$  and  $R^4$  each independently represents hydrogen or  $C_{1-8}$  alkyl; and

E represents a bond or a spacer having 1 to 6 atoms in its main chain;

G is  $-NR^{T1}-SO_2-$

wherein  $R^{T1}$  represents hydrogen,  $C_{1-8}$  alkyl which may be substituted,  $C_{2-8}$  alkenyl which may be substituted,  $C_{2-8}$  alkynyl which may be substituted or a 3- to 8-membered cyclic group which may be substituted;

or a salt thereof and a pharmaceutically acceptable carrier.

36. (currently amended): The pharmaceutical composition according to claim 35, which ~~is~~ has an activity of a chemokine receptor antagonist.

37. (original): The pharmaceutical composition according to claim 36, wherein the chemokine receptor is CCR4.

38. (currently amended): The pharmaceutical composition according to claim 37, which ~~is~~ has an activity for a preventive and/or therapeutic agent for treating CCR4-mediated diseases.

39. (original): The pharmaceutical composition according to claim 38, wherein the CCR4-mediated diseases are inflammatory and/or allergic diseases, metabolism and/or endocrine system diseases, cancer diseases or infections.

40. (original): The pharmaceutical composition according to claim 39, wherein the CCR4-mediated diseases are inflammatory and/or allergic diseases.

41. (original): The pharmaceutical composition according to claim 40, wherein the inflammatory and/or allergic diseases are respiratory diseases or dermatosis.

42. (original): The pharmaceutical composition according to claim 41, wherein the respiratory diseases are asthma.

43. (original): The pharmaceutical composition according to claim 41, wherein the dermatosis is atopic dermatitis.

44. (withdrawn-currently amended): A method for ~~preventing and/or~~ treating CCR4-mediated diseases in a mammal, which comprises administering to a mammal an effective amount of the compound according to claim 1 or a salt thereof.

45. (canceled).

46. (currently amended): A pharmaceutical composition which comprises: a ~~preventive and/or~~ therapeutic agent for CCR4-mediated diseases, which comprises the compound according to claim 1 or a salt thereof as an active ingredient; and one or at least two medicaments selected from a bronchodilator drug, a steroid drug, a non-steroidal antiinflammatory drug, a leukotriene receptor antagonist, a phosphodiesterase inhibitor, an immunosuppressant, an anti-allergic drug, a mediator-release inhibitor, an antihistamine drug, a metabolism promoter and/or a chemokine inhibitor.

47. (currently amended): The pharmaceutical composition according to claim 35, which ~~is has an activity of inhibiting an inhibitor of~~ effector cell function.

48. (currently amended): The pharmaceutical composition according to claim 47, which ~~is an inhibitor of~~ has an activity of inhibiting cell migration function.

49. (currently amended): The pharmaceutical composition according to claim 35, which ~~is has an activity of regulating a~~ TNF $\alpha$  regulator.